Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 November 2019 | Story Leonie Bolleurs | Photo Johan Roux
Prof Zakkie Pretorius
Prof Zakkie Pretorius, Research Fellow at the UFS Department of Plant Sciences.

Prof Zakkie Pretorius, Research Fellow, and Prof Botma Visser, Associate Professor, both from the Department of Plant Sciences at the University of the Free State (UFS), partnered in a ground-breaking research project headed by Dr Melania Figueroa from the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia. Together, these scientists solved a 20-year-old mystery, uncovering the origins of one of the world’s deadliest strains of cereal rust disease.

The manuscript, with the title, Emergence of the Ug99 lineage of the wheat stem rust pathogen through somatic hybridisation, was accepted for publication in Nature Communications.

According to a statement released by CSIRO, research shows that the devastating Ug99 strain of the wheat stem-rust fungus was not the result of a sexual cross between different rust strains as previously thought, but in fact was created when fungal strands simply fused to create a new hybrid strain.

This process is called somatic hybridisation and enables fungi to merge their cells and exchange genetic material without going through a complex sexual reproduction cycle. The study found that half of Ug99’s genetic material came from a strain that occurred in Southern Africa around 100 years ago and eventually spread to Australia.

The discovery implies that other crop-destroying rust strains could hybridise elsewhere with Ug99, for example, to exchange genetic material and create a whole new enemy.

While there was some speculation that rust strains could hybridise – based on laboratory studies in the 1960s as well as some earlier studies on the topic – this comprehensive research now provided the first genomic evidence that the process can generate new strains.

History of Ug99

Prof Pretorius was the first person to describe the dangerous Ug99 isolate, confirming the ability of the isolate to leave the Sr31 resistance gene ineffective (up to that time, effective against all known wheat stem-rust races). This laid the basis for international concern.

He named the field sample Ug99, based on the country of origin (Uganda) and year of sample collection (1999). 

“The Sr31 resistance gene and associated traits were so effective that the gene occurred in almost 70% of CIMMYT’s (Mexican-based International Maize and Wheat Improvement Center) spring wheat germplasm. In addition, many popular cultivars containing the gene were released around the world.”

“Ug99 then disappeared for a few years. When the race re-appeared in East Africa, it caused localised but severe epidemics,” he said.

Prof Pretorius continues: “Leading wheat breeders and pathologists were concerned that Ug99 could destroy wheat production in many global regions where wheat is critical for food security. Thus, in 2005, Dr Norman Borlaug, Nobel laureate and father of the green revolution, called for a meeting in Kenya where a global effort to combat the threat was initiated. The international wheat research community was mobilised and with funding primarily from the Bill and Melinda Gates Foundation and coordinated by Cornell University in the USA, research commenced.”

wheat stem rust

Wheat stem rust 14: Rust diseases are the cause of extensive crop losses each year. With this recent discovery, published in 
Nature Communications, scientists can now better identify the resistance genes which can be bred into wheat varieties to give crops 
long-lasting protection against rust. (Photo: Supplied) 

“From field trials in Kenya, it soon became apparent that 90% of the world’s wheat varieties were susceptible to Ug99. Although breeding and selection for resistance started in earnest, the pathogen adapted, gaining virulence for other previously effective resistance genes. At present, 13 races have been described within the Ug99 group occurring in 13 countries, mostly in Africa, but also in Yemen and Iran. Five of these races are present in South Africa, all confirmed by scientists from the UFS and ARC-Small Grain in Bethlehem. The original Ug99 has, however, never been detected in South Africa.”

Combined efforts

Rusts are common fungal diseases of plants. The spores of the fungus attach themselves to the stems and leaves of wheat plants and essentially suck the nutrients from the plant. Plants either die or produce shrivelled and low-quality grain. 

Group Leader at CSIRO, Dr Melania Figueroa, agrees that Ug99 is considered the most threatening of all rusts, as it has managed to overcome most stem rust-resistance genes used in wheat varieties.

“There is some good news, however; the better you know your enemy, the more equipped you are to fight against it. Knowing how these pathogens come about means we can better predict how they are likely to change in the future and better determine which resistance genes can be bred into wheat varieties to give long-lasting protection.”

Earlier this year, CSIRO worked with the University of Minnesota and the 2Blades Foundation to improve wheat resistance by stacking five resistance genes into the one wheat plant to combat wheat stem rust. 

The breakthrough came as Dr Figueroa’s group was sequencing Ug99 (then at the University of Minnesota), and at the same time a CSIRO team led by Dr Peter Dodds was sequencing Pgt21 in Australia (Pgt21 is a rust strain that was first seen in South Africa in the 1920s and believed to have been carried to Australia in the 1950s by wind currents). When the two groups compared results, they found that the two pathogens share an almost identical nucleus and therefore half of their DNA.

“This discovery will make it possible to develop better methods to screen for varieties with strong resistance to disease,” said Dr Figueroa.

Molecular fingerprinting

In addition to infection studies, molecular fingerprinting by members of the South African Ug99 race group led by Prof Botma Visser at the UFS, confirmed their genetic placement in context with Ug99 and other global stem rust races. The availability of the original Ug99 collection, along with other local rust isolates in long-term storage at the UFS, was essential to the success of the current research.

Despite the continued evolution of stem-rust variants, excellent progress has been made worldwide in the breeding of resistant wheat cultivars, including in South Africa. With funding from the Winter Cereal Trust, Dr Willem Boshoff, Senior Lecturer in the Department of Plant Sciences at the UFS, is responsible for the annual testing of all commercial wheat cultivars and advanced breeding lines for appropriate stem rust races.

Dr Melania Figueroa
Dr Melania Figueroa from the Commonwealth Scientific and Industrial Research Organisation (CSIRO). Photo: Kate Langford

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept